Cerus -

2/2/12
Cerus to Release Fourth Quarter and Year-End 2011 Results on February 28, 2012 more >

2/1/12
Cerus and Ilex BioTech Report INTERCEPT Platelet and Plasma System Approvals in... more >

1/9/12
Cerus Appoints Andrew Gomperts as Chief Business Officer more >

*About Cerus Corporation*			*2011 Annual Meeting*
	Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development. > More about Cerus		Meeting information and 2010 Annual Report are now available. > Information & downloads